ClinicalTrials.gg
CompletedNCT03881644Updated Jun 22, 2020

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

An interventional study of Imigran and Isotonic Saline in Migraine Without Aura, sponsored by Danish Headache Center. Completed at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-06-22.

Sponsored by Danish Headache Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Migraine without Aura by Danish Headache Center — none open to participants now, none under way, none of them phase 3. Migraine without Aura · Danish Headache Center.

Enrollment
4th of 16
37 · median 28
Started
2018
with 1 other
No phase
15 of 18
none open now
Registered
10th of 18
by date

Among the 18 studies in Migraine without Aura by Danish Headache Center, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 15 with no phase, and was the 10th registered.

Migraine without Aura

109 studies on the registry are indexed under Migraine without Aura; 18 are open to participants now.

Browse Migraine without Aura studies →

Open to participants now

None of the 18 studies in Migraine without Aura by Danish Headache Center is open now. The open studies under Migraine without Aura, anywhere →

Where they have run

Who these studies take

Of the 12 Migraine without Aura studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Migraine without Aura by Danish Headache Center as a file.
02

Study summary

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

Read the detailed description

Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced.

The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.

03

Conditions studied

  • Migraine Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of migraine, according to IHS criteria
  • weight between 50 - 100 kilograms
  • women in fertile age must not be pregnant and must use adequate

Exclusion criteria

Exclusion Criteria:

  • migraine more than 5 days per month in average over the past year
  • any primary headache other than migraine, apart from tension-type headache which must be less than 5 days per month
  • headache \< 48 hours before experimental day
  • migraine \< 72 hours before each experimental day
  • daily / frequent use of any medication apart from medication
  • use of any drug less than 5 times the half-life of the drug at the time of the experiment
  • women who are pregnant or breast-feeding at the time of the experiment
  • anamnestic or clinical signs of hypertension (systolic blood pressure > 150 mmHg and/or
  • diastolic blood pressure > 100 mmHg) or hypotension (systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg)
  • anamnestic or clinical signs of mental illness, or abuse of alcohol / drugs
  • patients with glaucoma or prostate hyperplasia
  • anamnestic or clinical symptoms of any sort that the investigating doctor deemed unfit for participating in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    PACAP38 + Imigran

    Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins AND Imigran infusion (0.4 mg/min) for 10 mins

    Drug: Imigran · Other: Pituitary adenylate cyclase-activating peptide-38

  • Placebo comparator
    PACAP38 + Isotonic Saline

    Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins AND Isotonic saline for 10 mins (placebo)

    Other: Isotonic Saline · Other: Pituitary adenylate cyclase-activating peptide-38

Interventions

  • All patients will undergo this intervention on one of two study days

    Also known as: Sumatriptan

  • OtherIsotonic Saline

    All patients will undergo this intervention on one of two study days

  • OtherPituitary adenylate cyclase-activating peptide-38

    All patients will undergo this intervention on both study days

    Also known as: PACAP38

06

What researchers measure

Primary outcomes

  1. Incidence of migraine

    Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine

    Time frame: From 0 to 12 hours after infusion

  2. Effect of Sumatriptan

    Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")

    Time frame: From 0 to 12 hours after infusion

Secondary outcomes

  1. Severity of flushing

    Facial skin blood flow (flushing) will be measured by laser doppler flowmetry to evaluate the severity of PACAP38-induced flushing with and without sumatriptan-treatment

    Time frame: From 0 to 4 hours after infusion

  2. Facial temperature

    PACAP38-induced temperature changes with and without sumatriptan-treatment measured by infrared thermography

    Time frame: From 0 to 4 hours after infusion

  3. Superficial temporal artery diameter

    Superficial temporal artery diameter after PACAP38 with and without sumatriptan-treatment measured by ultrasound

    Time frame: From 0 to 4 hours after infusion

  4. Severity of headache

    Severity of PACAP38-induced headache will be rated on a numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")

    Time frame: From 0 to 12 hours after infusion

07

Study locations

1 site
  • DanishHC
    Glostrup, DK-2600, Denmark
08

References and documents

Publications

  • Wienholtz NKF, Christensen CE, Zhang DG, Coskun H, Ghanizada H, Al-Karagholi MA, Hannibal J, Egeberg A, Thyssen JP, Ashina M. Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia. 2021 May;41(6):731-748. doi: 10.1177/0333102420975395. Epub 2021 Feb 10. PubMed 33567890 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2019, 16 months.

Of 29 non-industry interventional studies with no phase under Migraine without Aura, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 34. This study's 16 months is below that.

Counting every sponsor, half of 33 studies reached it within 19 months; a quarter within 12 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2019
First posted
Mar 19, 2019
StartActual
Jul 17, 2018
Primary completionActual
Dec 7, 2019
CompletionActual
Dec 7, 2019
Last update
Jun 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03881644
Responsible party
Nita Katarina Frifelt Wienholtz (Principal Investigator, Medical Doctor, PhD Student, Danish Headache Center) — Principal investigator
First posted
Mar 19, 2019
Start date
Jul 17, 2018
Primary completion
Dec 7, 2019
Completion
Dec 7, 2019
Last update
Jun 22, 2020

Study contacts

Messoud Ashina, MD,PhD,DMSc
study director · Danish Headache Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumatriptan

Start the discussion